The story behind NIOD Read the full story

NIOD — Non-Invasive Options in Dermal Science — is the high-concept, unapologetically technical arm of DECIEM, the Toronto company that upended the skincare industry. DECIEM was founded in 2013 by Brandon Truaxe, the brilliant and famously unconventional entrepreneur who built 'The Abnormal Beauty Company' into a phenomenon, and NIOD launched in 2015 as its most advanced, ingredient-obsessed brand.

Where its more famous sibling made minimalism cheap and accessible, NIOD went the opposite direction: dense, multi-ingredient formulas, encyclopedic label copy, and an audience of skincare devotees who wanted the most technically ambitious products on the market. Truaxe died in 2019, a loss the industry felt deeply, and DECIEM — including NIOD — is now owned by The Estée Lauder Companies, which took a majority stake and later full ownership.

Credit where due: NIOD's formulas are genuinely sophisticated, often incorporating higher concentrations and more unusual actives than almost anything else at its price, and the brand rewards people willing to read and understand what they're applying.

The honest read is that NIOD is brilliant and occasionally too clever for its own good. The formulations are legitimately advanced, but the dense, jargon-heavy positioning can outrun the clinical evidence for some claims, the products demand real knowledge to use well, and the complexity isn't always necessary for results. For an experienced, ingredient-literate user who wants cutting-edge, high-concept skincare and is willing to do the homework, NIOD is a rewarding brand; for a beginner, it's more than most routines need.

Founded
2015
Origin
Canada
Heritage
Established
Type
Clinical
Verdicts
0 Strong choice · 0 Good choice of 1 assessed
1 product reviewed

More about NIOD

NIOD (Non-Invasive Options in Dermal Science) launched in 2015 as the advanced arm of DECIEM (founded 2013 by Brandon Truaxe, who died in 2019); now owned by The Estée Lauder Companies, it offers sophisticated, high-concentration formulas, though its dense technical positioning can outrun the clinical evidence for some claims.